Interleukin-4 receptor alpha chain (IL-4Rα) is highly expressed on the surface of various human solid tumors. We designed a novel hybrid peptide termed IL4Rα-lytic peptide that targets the IL-4Rα chain. The IL4Rα-lytic peptide contains a target moiety to bind to IL-4Rα and a cellular toxic lytic peptide that selectively kills cancer cells. 
Introduction
By increasing knowledge of unique or overexpressed cell-surface antigens or receptors on tumor cells as targets, immunotoxin, one of the form of cancer therapy drug, has been developed over the last 3 to 4 decades. Immunotoxins are proteins that are composed of a target binding moiety (an antibody or growth factor that binds specifically to target cells) and a toxin moiety (a plant or bacterial toxin) (1) . Some immunotoxins have been tested in clinical trails and they exhibited some efficacy in most tested patients (2, 3, 4, 5) . An agent ONTAK that contains human interleukin-2 and truncated diphtheria toxin has been approved for use in cutaneous T-cell lymphoma (6) .
However, there are concerns of immunogenicity and hepatotoxicity caused by the immunotoxins (7, 8) . Moreover, due to their larger molecular sizes compared to chemical compounds or fragment antibody drugs, many immunotoxins might have difficulty in penetration into human tumor mass (6) . To reduce immunogenicity caused by the immunotoxins, several approaches have been used for the design of immunotoxins, such as chemical modification with polyethylene glycol (PEGylation) or fusion with a single-chain Fv of an antibody (9, 10) . PEGylation not only blocks immunogenicity but also prolongs half-life. But these immunotoxins still have larger Yang et al.
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molecular weight and are rather difficult to produce in larger scale.
To overcome these problems, a new hybrid peptide drug, which has similar concept with immunotoxin but smaller molecular weight, has been developed (11) .
Anti-cancer hybrid peptide (type I) contains target-binding amino acids and toxic amino acid sequences. These molecules are chemically stable, small, and can be synthesized by simple peptide chemistry (12) .
In the toxic part of the hybrid peptide, we have utilized a new lytic peptide (11) , which is stable when combined with targeting peptide with less toxic to normal cell lines when compared to original lytic peptide composed of a 15-amino-acid diastereomer composed of D-and L-amino acids (13).
High-affinity interleukin-4 receptor (IL-4R) are highly expressed on the surface of various human solid tumors including renal cell carcinoma, melanoma, breast carcinoma, ovarian carcinoma, glioblastoma, AIDS-related Kaposi's sarcoma, and head and neck squamous cell carcinoma (14, 15, 16, 17, 18, 19, 20) . IL-4R-targeted protein-based immunotoxin was being tested in the clinic for the treatment of human solid tumors (3, 21, 22) . The significance of expression of IL-4R on cancer cells still remains obscure. However, these receptors are able to mediate biological responses in cancer cells such as regulation of intercellular adhesion molecule-1 and major Yang et al.
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histocompatibility complex antigen expression, inhibition of cell growth, and induction of apoptosis (23) . The IL-4R system exists in three different types. Type I IL-4Rs are consisted of a major protein (IL-4Rα) and the IL-2Rγ chain (γc) (24, 25) . Type II IL-4Rs are composed of IL-4Rα and IL-13Rα1 chains. Type III IL-4Rs express all three chains. The IL-4Rs in solid tumor cells are composed of IL-4Rα and IL-13Rα1 chains (type II IL-4Rs) (26, 27, 28) .
These results prompted us to design a new hybrid peptide targeting IL-4Rα-overexpressing cancer cells, comprising of an IL-4Rα-binding moiety and the cellular membrane-lytic moiety, termed IL4Rα-lytic hybrid peptide. In this study, we examined the selective cytotoxicity of IL4Rα-lytic hybrid peptide to cancer cells in vitro, and antitumor activity of the peptide in vivo.
Yang et al. fetal bovine serum (BioWest, Miami, FL), 100 units/ml penicillin, and 100 µg/ml streptomycin (Nacarai Tesque, Kyoto, Japan). Cells were cultured in a humidified atmosphere of 5% CO 2 in air at 37 o C.
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Materials and methods
Cells
Peptides. The following peptides were purchased from Invitrogen (Carlsbad, CA):
1. Lytic peptide:
KLLLKLLKKLLKLLKKK (bold and underlined letters are D-amino acids.)
IL4Rα-lytic hybrid peptide
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KQLIRFLKRLDRNGGG KLLLKLLKKLLKLLKKK
All peptides were synthesized by use of solid-phase chemistry, purified to homogeneity (i.e. >80% purity) by reversed-phase high-pressure liquid chromatography, and assessed by mass spectrometry. Peptides were dissolved in water and buffered to PH 7.4.
Cell viability assay. Cells were seeded into 96-well plates at 3 × RT-PCR analysis. Total RNA of cells was isolated using NucleoSpin RNA kits (Macherey-Nagel, Germany). Each 0.5 µg of the RNA samples was used for an RT reaction. The reaction was performed in a final volume of 10 µl of reaction mixture using Rever TraAce RT kit (TOYOBO, Osaka, Japan Staining kit (Wako, Osaka, Japan). Data were analyzed using CellQuest Software.
Cell cycle analysis. Cell cycle analysis was performed as described previously (29 prepared from paraffin-embedded blocks were stained with H&E. Microscopy analysis was performed using Olympus DP25 microscopy (Tokyo, Japan).
Results
Design of IL4Rα-lytic peptide. It is known that various solid tumor cells highly express type II IL-4Rs which is composed of IL-4Rα and IL-13Rα1 chains (Fig. 1A) and IL-4Rα chain binds IL-4 with high affinity (Kd 20 to 300 pM). Fig. 1B shows the structure in the contact interface between human IL-4 and IL-4Rα. It was previously
shown that five positively charged residues (K77, R81, K84, R85, and R88) and a neighboring residue (N89) are important for binding of human IL-4 to IL-4Rα (30, 31, 32) . In addition, it was also reported that in the murine IL-4, the main binding site is 79QRLFRAFR86 and the residues R80, R83 and R86 play a crucial role for binding to IL-4Rα (33) . Three arginine residues R81, R85 and R88 of human IL-4 may mimic those arginine residues of mouse IL-4 in binding to IL-4Rα as shown in the alignment among human, bovine, murine, and rat IL-4 sequences (Fig. 1C) . From these results we have designed an IL-4 peptide, 77KQLIRFLKRLDRN89, which includes the critical amino acids R81, R85 and R88. SPR analysis showed that the designed peptide can bind to recombinant IL-4Rα with the Kd value of 2.90 × 10 -4 M by BIACORE system (data not shown). We then produced IL4Rα-lytic peptide, which contains lytic sequence (11) including three glycine as a spacer. Mutation analysis of IL4Rα-binding peptide also showed that the sequence shown here was the best to achieve the cytotoxic activity (Fig. 2B ).
Selective killing of cancer cell lines by IL4Rα-lytic peptide. To assess the cytotoxic activity of IL4Rα-lytic peptide, WST-8 assay was performed using normal and cancer cell lines treated with lytic peptide alone or IL4Rα-lytic peptide. As shown in Fig. 2C , both lytic peptide and IL4Rα-lytic peptide induced a concentration-dependent h, but the same concentration of lytic peptide alone did not induce cytotoxic activity (Fig. 3A) . On the other hand, neither lytic peptide alone nor IL4Rα-lytic peptide did induce optimal cell killing to PE (Fig. 3B) . These results suggest that IL4Rα-lytic hybrid peptide can rapidly and selectively kill cancer cells. Fig. S1A ). On the other hand, there was no significant difference on the percentage of sub-G1 and the value of MFI between treated and untreated cells after 1 h exposure to the same concentration of IL4Rα-lytic peptide (Fig 4C) . Furthermore, it was found that cell viability was quickly decreased within 1 h after the treatment with IL4Rα-lytic hybrid peptide ( Supplementary Fig. S1B ). Taken together with these results, it is suggested that the increases in the percentage of sub-G1 population and the MFI value of TUNEL assay were induced by secondary effect after rapid cancer cell death with IL4Rα-lytic hybrid peptide, and the apoptotic cell death induced by IL4Rα-lytic hybrid peptide is not primary. On the mouse xenograft model of human breast cancer MDA-MB-231, IL4Rα-lytic hybrid peptide also showed effective antitumor activity when administered by i.t. or i.v. injection ( Supplementary Fig. S2A ). No abnormal changes were observed in the major organs tissues obtained from the mice treated with IL4Rα-lytic hybrid peptide ( Supplementary Fig. S2B ). In addition, no remarkable loss of body weight was observed.
Characterization of cancer cell death mechanism by
Antitumor activity of
These results indicate that the IL4Rα-lytic hybrid peptide selectively targets to cancer cells inducing tumor regression without unexpected organ toxicities.
Discussion
It has been reported that several peptides composed of L-amino acids exhibited cytotoxic activity against cancer cell lines in vitro (34, 35) , however, most of these L-amino acid-based peptides also affected normal cells, limiting clinical usage.
Moreover, some of these L-amino acids peptides failed to exhibit desirable antitumor activity in vivo because these peptides lose cytotoxic activity in serum in the body circulation due to enzymatic degradation and binding to serum components (36) .
Supporting these reports, in the current study we also found that both a lytic peptide which is entirely composed of L-amino acids and a hybrid peptide composed of IL-4Rα binding moiety and the lytic moiety composed of L-amino acids, killed normal cell lines at a low concentration in vitro, and failed to show antitumor activity in vivo (data not shown). Papo N et al. developed a novel lytic peptide composed of DL-amino acids, which selectively killed cancer cells in vitro and in vivo (13). However, since we found that this lytic sequence was not suitable to combine with targeting moiety, we modified the DL-amino acids sequence to appropriately induce modest cancer cells killing, with less toxicity to normal cells in a lower concentration (11) . Similar to the lytic peptide previously reported, the new lytic sequence has positive charge and binds to negatively charged membranes (37) and subsequently lyses them (38) . It is known that the outer membrane of cancer cells contains a slightly more negatively charged phosphatidylserine than that of normal cells (39) . This fact probably, at least partly, contributes to the selectively killing cancer cells of lytic peptide.
By using peptide phage display and molecular modeling, Yao G et al. have showed that in murine the amino acid residues spanning from 76 to 86 (QRLFRAFR)
especially the residues R80, R83, and R86 play a crucial role in binding to the IL-4Rα
chain (39) . It has also been shown that residues K77, R81, K84, R85, R88, and N89 are Although increase in the percentage of sub-G1 population and TUNEL positive cells were found after 16 h treatment with IL4Rα-lytic peptide, these positive cells were not almost found after 1 h treatment with this peptide (Fig. 4C and Supplementary Fig.   S2A ). Since IL4Rα-lytic peptide quickly induced cancer cell death ( Fig. 3 and Supplementary Fig. S2B ), it is suggested that these apoptotic positive cells were induced by secondary effect, however, the detail mechanism of cancer cell death induced by IL4Rα-lytic hybrid peptide is still obscure.
It was also found that IL4Rα-lytic peptide exhibited high cytotoxic activity against cancer cells expressing IL-4Rα in vitro (Fig. 2C) , and that i.t. administration of this peptide dramatically inhibited the growth of pancreatic cancer BXPC-3 ( administration of this peptide induced dose-dependent regression of BXPC-3 (Fig. 5A) or MDA-MB-231 ( Supplementary Fig. S2A ) tumors. We assume that because i.t.
administration hold the drug locally at higher concentration in tumor, the antitumor effect exhibited was superior. No specific toxicity was found by either i.t. or i.v.
administration. Taken together, IL4Rα-lytic peptide might be a potent anticancer drug to IL-4Rα-expressing solid tumor, under the condition of local administration or the systemic administration in combination with the suitable drug delivery system.
In conclusion, in this study, we described the IL4Rα-lytic hybrid peptide targeting IL-4Rα in cancer cells. Further analyses to this drug including cytotoxic mechanisms, detailed safety profiles in animals, and justification of the appropriate usage in clinic will be necessary. These researches are currents ongoing in our laboratory. 
